#rigvir

New Publication Shows Surprisingly Positive Results With Oncolytic Virus Rigvir

Press Release – Aug 8, 2016 Riga, Latvia, August 8, 2016 (Newswire.com) – The surprisingly positive treatment outcomes using Rigvir virotherapy for late stages cancer patients were recently published. The patients of melanoma stage IV M1c, small cell lung cancer stage IIIA and histiocytic sarcoma stage IV started virotherapy with Rigvir within a few months after being diagnosed and are…

Prof.Aina Muceniece about virotherapy and cancer treatment.

Oncolytic virotherapy prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study. 

Virotherapy is an innovative therapy in cancer treatment, used both as monotherapy and also in complex with other known therapies. During virotherapy, the human body receives injections of live viruses with oncotropic and oncolytic properties that imply their ability to seek and destroy malignant tumor cells in the body.

Currently, cancer virotherapy sector offers only one registered medicine that contains a genetically not modified live virus and has been used in the clinical practice with good results.

Virotherapy with Riga virus is a safe, effective and mild therapy able to destroy cancer cells and prevent the development of metastases, as well as affect the immune system, inducing immune cell activity and mobilizing them to fight cancer.